Track topics on Twitter Track topics that are important to you
Florida-based biopharmaceutical company Oragenics (NYSE:OGEN) announced the pricing of an underwritten public offering of units for gross proceeds of $12 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. As quoted in the press release: The offering is comprised of 2,636,000 Class A Units, priced at a public offering price of … Continued
The post Oragenics Announces Pricing of $12 Million Underwritten Public Offering appeared first on Investing News Network.
Original Article: Oragenics Announces Pricing of $12 Million Underwritten Public OfferingNEXT ARTICLE
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...